Glutathione for Alzheimer's Disease

What Is This Study About?

Research suggests that low levels of glutathione, a protective substance made in the body, may be linked to Alzheimer's disease. Glutathione levels can be increased by taking supplements of glycine and cysteine, which combine in the body to make glutathione. This clinical trial will evaluate the effects of glycine-cysteine supplements in people with Alzheimer's disease. Participants will be randomly assigned to receive supplements of either glycine-cysteine or a placebo for 24 weeks. Participants will undergo MRI and PET brain imaging scans, assessments, and tests so researchers can measure changes in cognition, glutathione levels, brain cell energy use, and brain inflammation.

Do I Qualify To Participate in This Study?

Must have:

• Gradual and progressive memory loss for more than one year
• Montreal Cognitive Assessment score of 10 to 20
• Presence of tau deposits in brain based on a PET brain imaging scan 
• Availability of a study partner

Must NOT have:

• Hospitalization in past three months
• Known diabetes or use of anti-diabetic medications
• Known kidney or liver disease
• Untreated thyroid disease
• History of stroke, brain tumor, active heart failure, or active cancer (removable basal cell cancers are allowed)
• Untreated depression or other severe psychiatric disorders
• Pregnancy or nursing

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

Texas
Baylor College of Medicine Houston, TX 77030 Recruiting Rajagopal V Sekhar, MD 713-798-3908 rsekhar@bcm.edu

Who Sponsors This Study?

Lead: Baylor College of Medicine

Collaborator Sponsor

• Nantz National Alzheimer's Center, Methodist Hospital, Houston, TX

Source: ClinicalTrials.gov ID: NCT04740580